GSK bolsters oncology pipeline with $750m Chimagen TCE deal
GSK has secured the rights to Chimagen Biosciences’ trispecific T-cell engager (TCE) for multiple myeloma, signalling the big pharma company’s …
Post
-
-
Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics has drawn up plans to submit a New Drug Application (NDA) to US regulators for its psychedelic medicine, …
-
Cheplapharm to take over 20 medicines and three sites from Sanofi
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities …
-
FDA reduces monitoring time for Amgen’s Imdelltra infusions
The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing …
-
No more Nordisk: Novo’s latest trim is in its name
When Mike Doustdar joined Novo Nordisk as CEO, he emphasised corporate evolution. Now, a year later, he has delivered a …
-
FDA reduces monitoring time for Amgen’s Imdelltra infusions
The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing …
-
No more Nordisk: Novo’s latest trim is in its name
When Mike Doustdar joined Novo Nordisk as CEO, he emphasised corporate evolution. Now, a year later, he has delivered a …
-
Pressure intensifies on Novartis as bolt-on deal strategy faces major test
Novartis is facing scrutiny towards its merger and acquisition (M&A) strategy after trial setbacks have rocked investors’ confidence in its …
-
Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval
The US Food and Drug Administration (FDA) approved Scholar Rock’s rare neuromuscular disease therapy, Isemblyd (apitegromab), making it the first …
-
The rare disease revolution: The state of play for CGTs in orphan diseases
Rare diseases are chronic conditions that affect between 3.5% and 5.9% of the global population. About 80% of rare diseases …
-
HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
The National Institute for Health and Care Excellence (NICE) has recommended against reimbursement for Gilead’s twice-a-year PrEP medication lenacapavir, prompting …
-
ERS 2026: BMI, type-2 inflammation, and asthma attack risk
On 7 September, at the European Respiratory Society (ERS) 2026 Annual Meeting, a group of investigators, which included both academic …
-
Staunch biotech competition spurs new secretive tactics, shifts investor approach
In recent years, the pharma and biotech landscape has experienced several seismic geopolitical and technological shifts, including China’s rise to …
-
Exegenesis Bio and Modalis sign research deal for Duchenne therapy
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for …
-
ABEC to expand global manufacturing network with new Wilson facility
ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process …
